What To Know
- Atriomx Health, a Menlo Park, California-based developer of novel, non-invasive solutions for the detection and characterization of the underlying disease mechanisms of atrial fibrillation and other arrhythmias, announced today that it has secured a $10 million Series A financing.
- Atriomx Health notes Ajax Health and Zeus Health will co-lead the Series A round, the proceeds of which will be used to fund initial development and clinical study of the company’s hardware, software, and algorithmic solutions.
Atriomx Health, a Menlo Park, California-based developer of novel, non-invasive solutions for the detection and characterization of the underlying disease mechanisms of atrial fibrillation and other arrhythmias, announced today that it has secured a $10 million Series A financing.
Atriomx Health notes Ajax Health and Zeus Health will co-lead the Series A round, the proceeds of which will be used to fund initial development and clinical study of the company’s hardware, software, and algorithmic solutions.
“This financing will allow Atriomx to pursue the tremendous opportunity to transform the diagnosis and treatment of atrial fibrillation stemming from the application of novel AF detection and characterization capabilities to data that can be collected non-invasively,” said Duke Rohlen, CEO of Ajax Health and Zeus Health.
In conjunction with the Series A financing, Atriomx Health has appointed Mike Carter to serve as the company’s Chief Operating Officer. Mike brings experience productizing advanced algorithms from Kodiak Robotics, where he was a founding engineer and software lead.
